Global Endocrine Therapy Drugs for Breast Cancer Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Table of Contents

1 Endocrine Therapy Drugs for Breast Cancer Market Overview

• 1.1 Product Overview and Scope of Endocrine Therapy Drugs for Breast Cancer
• 1.2 Classification of Endocrine Therapy Drugs for Breast Cancer by Types
  • 1.2.1 Global Endocrine Therapy Drugs for Breast Cancer Revenue Comparison by Types (2019-2024)
  • 1.2.2 Global Endocrine Therapy Drugs for Breast Cancer Revenue Market Share by Types in 2018
  • 1.2.3 Tamoxifen
  • 1.2.4 Anastrozole
  • 1.2.5 Exemestane
  • 1.2.6 Letrozole
  • 1.2.7 Goserelin
  • 1.2.8 Fulvestrant
• 1.3 Global Endocrine Therapy Drugs for Breast Cancer Market by Application
  • 1.3.1 Global Endocrine Therapy Drugs for Breast Cancer Market Size and Market Share Comparison by Applications (2014-2024)
  • 1.3.2 Hospital
  • 1.3.3 Clinic
  • 1.3.4 Drug Center
  • 1.3.5 Other
• 1.4 Global Endocrine Therapy Drugs for Breast Cancer Market by Regions
  • 1.4.1 Global Endocrine Therapy Drugs for Breast Cancer Market Size (Million USD) Comparison by Regions (2014-2024)
  • 1.4.1 North America (USA, Canada and Mexico) Endocrine Therapy Drugs for Breast Cancer Status and Prospect (2014-2024)
  • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Endocrine Therapy Drugs for Breast Cancer Status and Prospect (2014-2024)
  • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Endocrine Therapy Drugs for Breast Cancer Status and Prospect (2014-2024)
  • 1.4.4 South America (Brazil, Argentina, Colombia) Endocrine Therapy Drugs for Breast Cancer Status and Prospect (2014-2024)
  • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Endocrine Therapy Drugs for Breast Cancer Status and Prospect (2014-2024)
• 1.5 Global Market Size of Endocrine Therapy Drugs for Breast Cancer (2014-2024)

2 Manufacturers Profiles

• 2.1 Teva
  • 2.1.1 Business Overview
  • 2.1.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
    • 2.1.2.1 Product A
    • 2.1.2.2 Product B
  • 2.1.3 Teva Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.2 Amneal Pharms
  • 2.2.1 Business Overview
  • 2.2.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
    • 2.2.2.1 Product A
    • 2.2.2.2 Product B
  • 2.2.3 Amneal Pharms Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.3 AstraZeneca
  • 2.3.1 Business Overview
  • 2.3.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
    • 2.3.2.1 Product A
    • 2.3.2.2 Product B
  • 2.3.3 AstraZeneca Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.4 Novartis
  • 2.4.1 Business Overview
  • 2.4.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
    • 2.4.2.1 Product A
    • 2.4.2.2 Product B
  • 2.4.3 Novartis Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.5 Intas Pharmaceuticals
  • 2.5.1 Business Overview
  • 2.5.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
    • 2.5.2.1 Product A
    • 2.5.2.2 Product B
  • 2.5.3 Intas Pharmaceuticals Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.6 Chemo
  • 2.6.1 Business Overview
  • 2.6.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
    • 2.6.2.1 Product A
    • 2.6.2.2 Product B
  • 2.6.3 Chemo Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.7 Accure Labs
  • 2.7.1 Business Overview
  • 2.7.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
    • 2.7.2.1 Product A
    • 2.7.2.2 Product B
  • 2.7.3 Accure Labs Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.8 Natco
  • 2.8.1 Business Overview
  • 2.8.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
    • 2.8.2.1 Product A
    • 2.8.2.2 Product B
  • 2.8.3 Natco Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.9 Zydus Pharmaceuticals
  • 2.9.1 Business Overview
  • 2.9.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
    • 2.9.2.1 Product A
    • 2.9.2.2 Product B
  • 2.9.3 Zydus Pharmaceuticals Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.10 Sanofi
  • 2.10.1 Business Overview
  • 2.10.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
    • 2.10.2.1 Product A
    • 2.10.2.2 Product B
  • 2.10.3 Sanofi Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.11 Pfizer
  • 2.11.1 Business Overview
  • 2.11.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
    • 2.11.2.1 Product A
    • 2.11.2.2 Product B
  • 2.11.3 Pfizer Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.12 Mylan
  • 2.12.1 Business Overview
  • 2.12.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
    • 2.12.2.1 Product A
    • 2.12.2.2 Product B
  • 2.12.3 Mylan Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.13 Wockhardt
  • 2.13.1 Business Overview
  • 2.13.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
    • 2.13.2.1 Product A
    • 2.13.2.2 Product B
  • 2.13.3 Wockhardt Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.14 Cipla
  • 2.14.1 Business Overview
  • 2.14.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
    • 2.14.2.1 Product A
    • 2.14.2.2 Product B
  • 2.14.3 Cipla Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.15 Actiza Pharmaceutical
  • 2.15.1 Business Overview
  • 2.15.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
    • 2.15.2.1 Product A
    • 2.15.2.2 Product B
  • 2.15.3 Actiza Pharmaceutical Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.16 Hikma Pharmaceuticals
  • 2.16.1 Business Overview
  • 2.16.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
    • 2.16.2.1 Product A
    • 2.16.2.2 Product B
  • 2.16.3 Hikma Pharmaceuticals Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.17 Shanghai Forward Technology
  • 2.17.1 Business Overview
  • 2.17.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
    • 2.17.2.1 Product A
    • 2.17.2.2 Product B
  • 2.17.3 Shanghai Forward Technology Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.18 Bayer
  • 2.18.1 Business Overview
  • 2.18.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
    • 2.18.2.1 Product A
    • 2.18.2.2 Product B
  • 2.18.3 Bayer Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.19 Liaoning Kangtai Pharmaceutical
  • 2.19.1 Business Overview
  • 2.19.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
    • 2.19.2.1 Product A
    • 2.19.2.2 Product B
  • 2.19.3 Liaoning Kangtai Pharmaceutical Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.20 Fu 'an Pharmaceutical Group
  • 2.20.1 Business Overview
  • 2.20.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
    • 2.20.2.1 Product A
    • 2.20.2.2 Product B
  • 2.20.3 Fu 'an Pharmaceutical Group Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.21 Apotex
  • 2.21.1 Business Overview
  • 2.2.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
    • 2.21.2.1 Product A
    • 2.21.2.2 Product B
  • 2.21.3 Apotex Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.22 Taro
  • 2.22.1 Business Overview
  • 2.22.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
    • 2.22.2.1 Product A
    • 2.22.2.2 Product B
  • 2.22.3 Taro Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.23 Sun Phamaceutical
  • 2.23.1 Business Overview
  • 2.23.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
    • 2.23.2.1 Product A
    • 2.23.2.2 Product B
  • 2.23.3 Sun Phamaceutical Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.24 Intas Pharmaceuticals
  • 2.24.1 Business Overview
  • 2.24.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
    • 2.24.2.1 Product A
    • 2.24.2.2 Product B
  • 2.24.3 Intas Pharmaceuticals Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.25 Chemo
  • 2.25.1 Business Overview
  • 2.25.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
    • 2.25.2.1 Product A
    • 2.25.2.2 Product B
  • 2.25.3 Chemo Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.26 Accure Labs
  • 2.26.1 Business Overview
  • 2.26.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
    • 2.26.2.1 Product A
    • 2.26.2.2 Product B
  • 2.26.3 Accure Labs Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.27 Sun Pharmaceutical
  • 2.27.1 Business Overview
  • 2.27.2 Endocrine Therapy Drugs for Breast Cancer Type and Applications
    • 2.27.2.1 Product A
    • 2.27.2.2 Product B
  • 2.27.3 Sun Pharmaceutical Endocrine Therapy Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)

3 Global Endocrine Therapy Drugs for Breast Cancer Market Competition, by Players

• 3.1 Global Endocrine Therapy Drugs for Breast Cancer Revenue and Share by Players (2014-2019)
• 3.2 Market Concentration Rate
  • 3.2.1 Top 5 Endocrine Therapy Drugs for Breast Cancer Players Market Share
  • 3.2.2 Top 10 Endocrine Therapy Drugs for Breast Cancer Players Market Share
• 3.3 Market Competition Trend

4 Global Endocrine Therapy Drugs for Breast Cancer Market Size by Regions

• 4.1 Global Endocrine Therapy Drugs for Breast Cancer Revenue and Market Share by Regions
• 4.2 North America Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 4.3 Europe Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 4.4 Asia-Pacific Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 4.5 South America Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 4.6 Middle East and Africa Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

5 North America Endocrine Therapy Drugs for Breast Cancer Revenue by Countries

• 5.1 North America Endocrine Therapy Drugs for Breast Cancer Revenue by Countries (2014-2019)
• 5.2 USA Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 5.3 Canada Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 5.4 Mexico Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

6 Europe Endocrine Therapy Drugs for Breast Cancer Revenue by Countries

• 6.1 Europe Endocrine Therapy Drugs for Breast Cancer Revenue by Countries (2014-2019)
• 6.2 Germany Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 6.3 UK Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 6.4 France Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 6.5 Russia Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 6.6 Italy Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

7 Asia-Pacific Endocrine Therapy Drugs for Breast Cancer Revenue by Countries

• 7.1 Asia-Pacific Endocrine Therapy Drugs for Breast Cancer Revenue by Countries (2014-2019)
• 7.2 China Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 7.3 Japan Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 7.4 Korea Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 7.5 India Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 7.6 Southeast Asia Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

8 South America Endocrine Therapy Drugs for Breast Cancer Revenue by Countries

• 8.1 South America Endocrine Therapy Drugs for Breast Cancer Revenue by Countries (2014-2019)
• 8.2 Brazil Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 8.3 Argentina Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 8.4 Colombia Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

9 Middle East and Africa Revenue Endocrine Therapy Drugs for Breast Cancer by Countries

• 9.1 Middle East and Africa Endocrine Therapy Drugs for Breast Cancer Revenue by Countries (2014-2019)
• 9.2 Saudi Arabia Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 9.3 UAE Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 9.4 Egypt Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 9.5 Nigeria Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 9.6 South Africa Endocrine Therapy Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

10 Global Endocrine Therapy Drugs for Breast Cancer Market Segment by Type

• 10.1 Global Endocrine Therapy Drugs for Breast Cancer Revenue and Market Share by Type (2014-2019)
• 10.2 Global Endocrine Therapy Drugs for Breast Cancer Market Forecast by Type (2019-2024)
• 10.3 Tamoxifen Revenue Growth Rate (2014-2024)
• 10.4 Anastrozole Revenue Growth Rate (2014-2024)
• 10.5 Exemestane Revenue Growth Rate (2014-2024)
• 10.6 Letrozole Revenue Growth Rate (2014-2024)
• 10.7 Goserelin Revenue Growth Rate (2014-2024)
• 10.8 Fulvestrant Revenue Growth Rate (2014-2024)

11 Global Endocrine Therapy Drugs for Breast Cancer Market Segment by Application

• 11.1 Global Endocrine Therapy Drugs for Breast Cancer Revenue Market Share by Application (2014-2019)
• 11.2 Endocrine Therapy Drugs for Breast Cancer Market Forecast by Application (2019-2024)
• 11.3 Hospital Revenue Growth (2014-2019)
• 11.4 Clinic Revenue Growth (2014-2019)
• 11.5 Drug Center Revenue Growth (2014-2019)
• 11.6 Other Revenue Growth (2014-2019)

12 Global Endocrine Therapy Drugs for Breast Cancer Market Size Forecast (2019-2024)

• 12.1 Global Endocrine Therapy Drugs for Breast Cancer Market Size Forecast (2019-2024)
• 12.2 Global Endocrine Therapy Drugs for Breast Cancer Market Forecast by Regions (2019-2024)
• 12.3 North America Endocrine Therapy Drugs for Breast Cancer Revenue Market Forecast (2019-2024)
• 12.4 Europe Endocrine Therapy Drugs for Breast Cancer Revenue Market Forecast (2019-2024)
• 12.5 Asia-Pacific Endocrine Therapy Drugs for Breast Cancer Revenue Market Forecast (2019-2024)
• 12.6 South America Endocrine Therapy Drugs for Breast Cancer Revenue Market Forecast (2019-2024)
• 12.7 Middle East and Africa Endocrine Therapy Drugs for Breast Cancer Revenue Market Forecast (2019-2024)

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology